These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 19107783)

  • 1. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease.
    Hyams JS; Lerer T; Griffiths A; Pfefferkorn M; Kugathasan S; Evans J; Otley A; Carvalho R; Mack D; Bousvaros A; Rosh J; Mamula P; Kay M; Crandall W; Oliva-Hemker M; Keljo D; LeLeiko N; Markowitz J;
    Inflamm Bowel Dis; 2009 Jun; 15(6):816-22. PubMed ID: 19107783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease.
    Markowitz J; Hyams J; Mack D; Leleiko N; Evans J; Kugathasan S; Pfefferkorn M; Mezoff A; Rosh J; Tolia V; Otley A; Griffiths A; Moyer MS; Oliva-Hemker M; Wyllie R; Rothbaum R; Bousvaros A; Del Rosario JF; Hale S; Lerer T;
    Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1124-9. PubMed ID: 16861053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome following infliximab therapy in children with ulcerative colitis.
    Hyams JS; Lerer T; Griffiths A; Pfefferkorn M; Stephens M; Evans J; Otley A; Carvalho R; Mack D; Bousvaros A; Rosh J; Grossman A; Tomer G; Kay M; Crandall W; Oliva-Hemker M; Keljo D; LeLeiko N; Markowitz J;
    Am J Gastroenterol; 2010 Jun; 105(6):1430-6. PubMed ID: 20104217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.
    Sprakes MB; Ford AC; Warren L; Greer D; Hamlin J
    J Crohns Colitis; 2012 Mar; 6(2):143-53. PubMed ID: 22325168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
    Louis E; Mary JY; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Dupas JL; Pillant H; Picon L; Veyrac M; Flamant M; Savoye G; Jian R; Devos M; Porcher R; Paintaud G; Piver E; Colombel JF; Lemann M;
    Gastroenterology; 2012 Jan; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
    Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.
    Ruemmele FM; Lachaux A; Cézard JP; Morali A; Maurage C; Giniès JL; Viola S; Goulet O; Lamireau T; Scaillon M; Breton A; Sarles J;
    Inflamm Bowel Dis; 2009 Mar; 15(3):388-94. PubMed ID: 19023899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.
    Punati J; Markowitz J; Lerer T; Hyams J; Kugathasan S; Griffiths A; Otley A; Rosh J; Pfefferkorn M; Mack D; Evans J; Bousvaros A; Moyer MS; Wyllie R; Oliva-Hemker M; Mezoff A; Leleiko N; Keljo D; Crandall W;
    Inflamm Bowel Dis; 2008 Jul; 14(7):949-54. PubMed ID: 18306311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.
    Drobne D; Bossuyt P; Breynaert C; Cattaert T; Vande Casteele N; Compernolle G; Jürgens M; Ferrante M; Ballet V; Wollants WJ; Cleynen I; Van Steen K; Gils A; Rutgeerts P; Vermeire S; Van Assche G
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):514-521.e4. PubMed ID: 25066841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
    Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
    D'Haens G; Vermeire S; Lambrecht G; Baert F; Bossuyt P; Pariente B; Buisson A; Bouhnik Y; Filippi J; Vander Woude J; Van Hootegem P; Moreau J; Louis E; Franchimont D; De Vos M; Mana F; Peyrin-Biroulet L; Brixi H; Allez M; Caenepeel P; Aubourg A; Oldenburg B; Pierik M; Gils A; Chevret S; Laharie D;
    Gastroenterology; 2018 Apr; 154(5):1343-1351.e1. PubMed ID: 29317275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort.
    de Ridder L; Rings EH; Damen GM; Kneepkens CM; Schweizer JJ; Kokke FT; Benninga MA; Norbruis OF; Hoekstra JH; Gijsbers CF; Escher JC
    Inflamm Bowel Dis; 2008 Mar; 14(3):353-8. PubMed ID: 18069674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease.
    Punekar YS; Sunderland T; Hawkins N; Lindsay J
    Value Health; 2010; 13(2):188-95. PubMed ID: 19883407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease.
    Grossi V; Lerer T; Griffiths A; LeLeiko N; Cabrera J; Otley A; Rick J; Mack D; Bousvaros A; Rosh J; Grossman A; Saeed S; Kay M; Boyle B; Oliva-Hemker M; Keljo D; Pfefferkorn M; Faubion W; Kappelman MD; Sudel B; Markowitz J; Hyams JS
    Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1748-56. PubMed ID: 25911120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease.
    Church PC; Guan J; Walters TD; Frost K; Assa A; Muise AM; Griffiths AM
    Inflamm Bowel Dis; 2014 Jul; 20(7):1177-86. PubMed ID: 24865777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.
    Fischer M; Campbell SC; Calley CSJ; Helper DJ; Chiorean MV; Fadda HM
    Dig Dis Sci; 2017 Nov; 62(11):3131-3137. PubMed ID: 28986660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing infliximab therapy in pediatric Crohn's disease.
    Kirschner BS; Huo D
    Gastroenterology; 2007 Mar; 132(3):1167-70. PubMed ID: 17383435
    [No Abstract]   [Full Text] [Related]  

  • 19. [Efficacy of infliximab in treatment of pediatric Crohn's disease in China].
    Luo Y; Yu J; Zhao H; Peng K; Lou J; Ma M; Chen J
    Zhonghua Er Ke Za Zhi; 2014 Sep; 52(9):688-92. PubMed ID: 25476432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
    Bortlik M; Duricova D; Malickova K; Machkova N; Bouzkova E; Hrdlicka L; Komarek A; Lukas M
    J Crohns Colitis; 2013 Oct; 7(9):736-43. PubMed ID: 23200919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.